Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.
Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study.
复制标题
DOI：
10.1097/cnd.0b013e31822c34dd
复制
发表时间：
2011-12-01
影响因子：
--
通讯作者：
Noyes, Katia
中科院分区：
文献类型：
--
作者：
Heatwole, Chad;Johnson, Nicholas;Noyes, Katia
目的：比较静脉注射免疫球蛋白（IVIG）与血浆置换治疗重症肌无力危象患者的短期经济成本。方法：对IVIG与血浆置换治疗重症肌无力危象进行逐项比较成本最小化分析。计算基于每种治疗的实施成本，相关的住院时间和治疗已知并发症的预测成本。根据每种疗法的总成本概况，提出了一种成本优效性确定方法。结果：总成本的差异有利于IVIG超过血浆置换，平均每例患者节省22，326美元。敏感性分析表明，总成本是高度依赖于IVIG剂量，住院时间，血浆交换days required.CONCLUSIONS：使用IVIG重症肌无力危象可能是一个短期的成本最小化治疗相比，血浆交换。需要额外的前瞻性研究来评估这些疗法的扩展成本和功效。
OBJECTIVE: To compare the short-term financial costs of treating a patient in myasthenia gravis crisis with intravenous immunoglobulin (IVIG) versus plasma exchange.METHODS: An itemized comparative cost-minimization analysis of IVIG versus plasma exchange for myasthenia gravis crisis was performed. Calculations were based on each therapy's implementation cost, associated hospitalization times, and predicted cost to treat known complications. A cost superiority determination was proposed based on the total cost profile of each therapy.RESULTS: The difference in total cost favored IVIG over plasma exchange with an average savings of $22,326 per patient. Sensitivity analysis demonstrated that overall costs are highly dependent on IVIG dosing, hospital lengths of stay, and the number of plasma exchange days required.CONCLUSIONS: The use of IVIG for myasthenia gravis crisis may be a short-term cost minimizing therapy compared with plasma exchange. Additional prospective studies are required to evaluate the extended cost profile and efficacy of these therapies.